Effects of proton pump inhibitors on mycophenolate trough concentration in renal transplant recipients
JI Zi-li1， ZHAO Li2，CHE Hui3，LIU Xiao2，LI Peng-mei2， LIU Jun-yang2， ZHANG Lei2， ZHANG Xiang-lin2*
Author information+
1. Beijing Fengtai Hospital， Beijing 100071， China；2.Department of Pharmacy，China-Japan Friendship Hospital，Beijing 100029，China；3.PLA Institute for Drug Control， Beijing 100071，China
{{custom_zuoZheDiZhi}}
{{custom_authorNodes}}
{{custom_bio.content}}
{{custom_bio.content}}
{{custom_authorNodes}}
Collapse
History+
Received
Revised
Published
2011-11-11
2011-11-11
2011-08-15
Issue Date
2011-08-15
Abstract
OBJECTIVE To explore the impact of PPIs therapy on mycophenolate mofetil（MMF） trough concentration in renal transplant recipients. METHODS Patients were enrolled after receiving de novo kidney transplantation in 2009-2010. The pharmacotherapy regimen was tacrolimus、mycophenolate mofiteil and prednisone. The concentration of mycophenolic acid in plasma was detected with HPLC. RESULTS The trough concentration of MPA in the patients using PPIs after kidney transplantation was 2.58±2.63μg·mL-1， and that in the patients after withdrawing PPIs was （1.98±1.57）μg·mL-1. There was no significance difference between these two groups. The clinical relevance between MPA trough concentration and creatinine or urea was minor. CONCLUSION Compared with the group without PPIs， PPIs therapy in combination with MMF does not appear to have a significant impact on early MPA trough concentration. The strategy of fixed dose of MMF can generate adequate concentration in patients whether or not receiving PPIs therapy.
JI Zi-li;ZHO Li;CHE Hui;LIU Xio;LI Peng-mei;LIU Jun-yng;ZHNG Lei;ZHNG Xing-lin.
Effects of proton pump inhibitors on mycophenolate trough concentration in renal transplant recipients[J]. Chinese Pharmaceutical Journal, 2011, 46(16): 1273-1275
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] LI P M， ZHANG X L， TANG K， et al. Determination of mycophcnolic acid concentration in human plasma and its application to therapeutic drug monitoring in renal transplantation patient[J]. Chin Pharm J(中国药学杂志)，2007，42(19)：1490-1493. [2] TROPPMANN C， PAPALOIS B E， CHIOU A， et al. Incidence， complications， treatment， and outcome of ulcers of the upper gastrointestinal tract after renal transplantation during the cyclosporine era[J]. J Am Coll Surg， 1995， 180(4)：433-443. [3] CHEN K J， CHEN C H， CHENG C H， et al. Risk factors for peptic ulcer disease in renal transplant patient-11 years of experience from a single center[J]. Clin Nephrol， 2004，62(1)：14-20. [4] SUWELACK B， GABRIELS G， VOLMER S， et al. Resolution of severe MMF related gastrointestinal adverse events following conversion to entericcoated mycophenolate sodium[J]. Transplantation， 2005，79(8)：987-988. [5] ALTOMARE J F， SMITH R E， POTDAR S， et al. Delayed gastric ulcer healing associated with sirolimus[J]. Transplantation， 2006， 82(3)：437-438. [6] STAATZ C E， TETT S E. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients[J]. Clin Pharmacokinet， 2007， 46(1)：13-58. [7] KIBERD BA， WROBEL M， DANDAVINO R， et al. The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation： evidence from the CLEAR study[J]. Ther Drug Monit， 2011 Feb;33(1)：120-123. [8] BULLINGHAM R， SHAH J， GOLDBLUM R， et al. Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients[J]. Br J Clin Pharmacol， 1996，41(6)：513-516. [9] KOFLER S， DEUTSCH M-A， BIGDELI AK， et al. Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients[J]. J Heart Lung Transplant，2009，28(6)：605-611. [10] KOFLER S， SHVETS N， BIGDELI AK， et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients—a prospective case-controlled study[J]. Am J Transplant，2009，9(7)：1650-1656. [11] RUPPRECHT K， SCHMIDT C， RASPE′ A， et al. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers[J]. J Clin Pharmacol，2009，49(10)：1196-1201. [12] MIURA M， SATOH S， INOUE K， et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation[J]. Ther Drug Monit，2008，30(1)：46-51. [13] SCHAIER M， SCHOLL C， SCHARPF D， et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil[J]. Rheumatology， 2010，49(11)：2061-2067. [14] VAN GELDER T， PESCOVITZ M， ELZEIN H， et al. The effect of gastric pH modulators on the pharmacokinetics of mycophenolate mofetil (MMF) in de novo renal transplant patients[J]. Presented at the International Congress of the Transplantation Society 2004 [Abstract]. [15] FAN P Y W， BARRACLOUGH K A， ISBEL N M， et al. Impact of omeprazole on mycophenolic acid pharmacokinetics in adult kidney transplant recipients[J]. Presented at the International Congress of the Transplantation Society， 2010 [Abstract]. [16] POOMMIPANIT N B， BUNNAPRADIST S. CNI sparing： short-term results promising， but long-term data needed[J]. Nephrology times， 2009，2(8)：6-10.
PDF(656 KB)
